Kodiak Sciences (KOD) Amortization of Deferred Charges (2017 - 2026)
Kodiak Sciences (KOD) posted Amortization of Deferred Charges of $2.2 million for Q1 2026, up 13.19% on a QoQ basis from $2.0 million in Q4 2025, and up 4.99% year-over-year from $2.1 million in Q1 2025.
Kodiak Sciences (KOD) Amortization of Deferred Charges (2017 - 2026) Analysis & Trends
Kodiak Sciences' Amortization of Deferred Charges history runs 9 years deep, the most recent figure standing at $2.2 million for Q1 2026.
- Quarterly Amortization of Deferred Charges rose 4.99% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.1 million (down 0.98% YoY) and the FY2025 annual result came in at $8.0 million, changed 0.05% from the prior year.
- Amortization of Deferred Charges was $2.2 million for Q1 2026 at Kodiak Sciences, up from $2.0 million in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $2.2 million in Q1 2026 and bottomed at $1.7 million in Q3 2022.
- A 5-year average of $1.9 million and a median of $1.9 million in 2025 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges dropped 10.34% — and 2023, when it gained 14.57%.
- Kodiak Sciences' Amortization of Deferred Charges stood at $1.7 million in 2022, then advanced by 10.93% to $1.9 million in 2023, then climbed by 6.09% to $2.1 million in 2024, then decreased by 4.13% to $2.0 million in 2025, then grew by 13.19% to $2.2 million in 2026.
- Business Quant data shows KOD's Amortization of Deferred Charges at $2.2 million in Q1 2026, $2.0 million in Q4 2025, and $2.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 472.75 Bn | 467.96 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.14 Bn | 114.89 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn |
| 10 | Kodiak Sciences | 2.62 Bn | 2.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.23 Mn |
| Mar 31, 2026 | 2.23 Mn |
| Dec 31, 2025 | 1.97 Mn |
| Dec 31, 2025 | 1.97 Mn |
| Sep 30, 2025 | 1.95 Mn |
| Sep 30, 2025 | 1.95 Mn |
| Jun 30, 2025 | 1.94 Mn |
| Jun 30, 2025 | 1.94 Mn |
| Mar 31, 2025 | 2.13 Mn |
| Mar 31, 2025 | 2.13 Mn |
| Dec 31, 2024 | 2.06 Mn |
| Dec 31, 2024 | 2.06 Mn |
| Sep 30, 2024 | 2.01 Mn |
| Sep 30, 2024 | 2.01 Mn |
| Jun 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | 1.99 Mn |
| Mar 31, 2024 | 1.94 Mn |
| Mar 31, 2024 | 1.94 Mn |
| Dec 31, 2023 | 1.94 Mn |
| Dec 31, 2023 | 1.94 Mn |